Breath takeout gives Zambon lung transplant candidate, U.S. foothold
By Elizabeth S. Eaton, Staff Writer | Jul 25, 2019 | 8:06 AM GMT
Italian pharma Zambon is acquiring Sofinnova Partners portfolio company Breath Therapeutics for €140 million ($156 million) up front to expand its respiratory pipeline and establish a foothold in the U.S.
Shareholders of Breath Therapeutics B.V.
Read the full 340 word article
User Sign In
This article may not be distributed to non-subscribers
PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD